Quote:

---

That said, once we get past the hold, is there a good reason the company is not looking at an influenza trial and it's 300-500k annual deaths? From my unknowledgeable perspective, that would seem to me a relatively easier trial design and a shorter, lower cost path to follow.

---

I first posited leronlimab for pulmonary inflammation in severe influenza before Covid came to the forefront. The trial design would mimic the Covid trials but would be only worthwhile if we were allowed to use our drug through the entire trial. It would be a short trial length, but I suspect the trial would take a very long time to enroll. The amount of deaths due to severe influenza in the U.S. would be a fraction of that 500k.